Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4D | Q6B0I6 | 2/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 7/20 | 0.43 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | UCHL1 | P09936 | 4/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8221589 | 0.86 | GPR119 (0.43) | KDM4DUSP30GPR119UCHL1MMP13 | |
| SCHEMBL4726619 | 0.85 | DAGLB (0.42) | — | |
| SCHEMBL4726621 | 0.85 | DAGLB (0.42) | — | |
| SCHEMBL1795627 | 0.82 | GPR119 (0.43) | GPR119UCHL1 | |
| SCHEMBL25969334 | 0.82 | GPR119 (0.43) | GPR119UCHL1 | |
| SCHEMBL3443002 | 0.82 | GPR119 (0.43) | GPR119UCHL1 | |
| SCHEMBL3443180 | 0.81 | GPR119 (0.46) | USP30POLBGPR119KDM4E | |
| SCHEMBL3538308 | 0.81 | GPR119 (0.43) | GPR119UCHL1 | |
| SCHEMBL3442875 | 0.80 | RIPK1 (0.45) | GPR119UCHL1 | |
| SCHEMBL4781869 | 0.80 | USP30 (0.43) | USP30GPR119UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008018639-A2 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | WO | disclosed |
| WO-2008018639-A2 | GLYCINE TRANSPORTER INHIBITOR | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2008-02-14 | — | — | WO | disclosed |